covid
Buscar en
Seminarios de la Fundación Española de Reumatología
Toda la web
Inicio Seminarios de la Fundación Española de Reumatología Valor diagnóstico del HLA-B27 en las espondiloartropatías
Información de la revista
Vol. 9. Núm. 1.
Páginas 26-34 (marzo 2008)
Compartir
Compartir
Descargar PDF
Más opciones de artículo
Vol. 9. Núm. 1.
Páginas 26-34 (marzo 2008)
Revisiones
Acceso a texto completo
Valor diagnóstico del HLA-B27 en las espondiloartropatías
Visitas
33685
Beatriz Arca Barca, Antonio Mera Varela
Hospital Clínico Universitario de Santiago de Compostela. Santiago de Compostela. A Coruña. España
Este artículo ha recibido
Información del artículo
Resumen

Las espondiloartropatías constituyen un grupo de enfermedades inflamatorias crónicas que comparten un amplio abanico de manifestaciones clínicas, entra las que destacan la afectación de las articulaciones sacroilíacas y de la columna vertebral, oligoartritis periférica de predominio en miembros inferiores y entesitis. La patogenia no es bien conocida, aunque todas ellas (espondilitis anquilosante, artritis reactiva, artritis psoriásica, artritis asociada a enfermedad inflamatoria intestinal crónica, algunas formas de artritis idiopática juvenil y espondiloartropatías indiferenciadas) parecen responder a una base genética común. En los últimos años se han postulado distintas teorías acerca de la patogenia de la enfermedad. Muchas de ellas apuntan al HLA-B27, molécula del complejo mayor de histocompatibilidad, como factor genético predisponente. Pero la existencia de sujetos B27 positivos que no desarrollan ninguna espondiloartropatía, así como individuos B27 negativos con alguna de estas enfermedades, plantea dudas acerca de la patogenia y el papel que puede desempeñar el B27. Hasta el presente, el diagnóstico se ha basado fundamentalmente en criterios clínicos y radiológicos (criterios de Nueva York modificados, criterios del Grupo Europeo, criterios de Bernard Amor). En esta revisión se muestra el conocimiento actual del valor diagnóstico del HLA-B27 en las espondiloartropatías.

Palabras clave:
Espondiloartropatías
HLA-B27
Diagnóstico
Abstract

Spondyloarthropathies are chronic inflammatory diseases that share a wide range of clinical features, including spondylitis, sacroiliitis, pauciarticular peripheral arthritis, and enthesopathy. The pathogenesis is not well known, although all these diseases (ankylosing spondylitis, reactive arthritis, psoriatic arthritis, arthritis in patients with inflammatory bowel disease, some forms of juvenile idiopathic arthritis, and undifferentiated spondyloarthropathies) seem to have common genetic bases. In the last few years, several theories on the pathogenesis of these diseases have been postulated. Many of these theories have implicated HLAB27, a molecule of the major histocompatibility complex, as a predisposing genetic factor. However, because some B27-positive individuals are disease-free while some B27 negative individuals develop one of these diseases, the pathogenic role of HLA-B27 remains unclear. To date, the diagnosis of spondyloarthropathies has mainly been based on clinical and radiographic criteria (New York modified criteria, European Study Group criteria, Bernard Amor criteria). The present review aims to describe current knowledge on the value of HLA-B27 in the diagnosis of spondyloarthropathies.

Key words:
Spondyloarthropathies
HLA-B27
Diagnosis
El Texto completo está disponible en PDF
Bibliografía
[1.]
D. Boulware, F. Arnett, J. Cush, P. Lipsky, R. Bennet, H. Mielants, et al.
The seronegative spondyloarthropathies.
Clinical Primer of Rheumatology, pp. 127-163
[2.]
F. De Keyser.
Spondyloarthropathies [editorial comment].
Curr Opin Rheumatol, 18 (2006), pp. 329-331
[3.]
J.D. Reveille.
The genetic basis of ankylosing spondylitis.
Curr Opin Rheumatol, 18 (2006), pp. 332-341
[4.]
M.A. Khan, A. Mathieu, R. Sorrentino, N. Akkoc.
The pathogenetic role oh HLA-B27 and its subtipes.
Autoimmun Rev, 6 (2007), pp. 183-189
[5.]
M. Rudwaleit, D. Van der Heijde, M.A. Khan, J. Braun, J. Sieper.
How to diagnose axial spondyloarthritis early.
Ann Rheum Dis, 63 (2004), pp. 535-543
[6.]
M.T. Seipp, M. Erali, R.L. Wies, C. Wittwer.
HLA-B27 typing: evaluation of an allele-specific PCR melting assay and two flow cytometric antigen assays.
Cytometry Part B (Clinical Cytometry), 63B (2005), pp. 10-15
[7.]
M. Ramos, J.A. López de Castro.
HLA-B27 and the pathogenesis of spondyloarthritis.
Tissue Antigens, 60 (2002), pp. 191-205
[8.]
D.R. Madden, J.C. Gorga, J.L. Strominger, D.C. Wiley.
The structure of HLA-B27 reveals nonamer self peptides bound in an extended conformation.
Nature, 353 (1991), pp. 321-325
[9.]
D.R. Madden, J.C. Gorga, J.L. Strominger, D.C. Wiley.
The threedimensional structure of HLA-B27 at 2.1 A resolution suggests a general mechanism for tight peptide binding to MHC.
Cell, 70 (1992), pp. 1035-1048
[10.]
M.J. Turner, R.A. Colbert.
HLA-B27 and pathogenesis of spondyloarthropathies.
Curr Opin Rheumatol, 14 (2002), pp. 367-372
[11.]
M.A. Khan.
HLA-B27 and its subtypes in world population.
Curr Opin Rheumatol, 7 (1995), pp. 263-269
[12.]
M.A. Khan.
Update: the twenty subtypes of HLA-B27.
Curr Opin Rheumatol, 12 (2000), pp. 235-238
[13.]
L. Sesma, V. Montserrat, J.R. Lamas, A. Marina, J. Vázquez, J.A. López de Castro.
The peptide repertoires of HLA-B27 subtypes differentially associated to spondyloarthropathy (B*2704 and B*2706) differ by specific changes at the three anchor positions.
J Biol Chem, 277 (2002), pp. 16744-16779
[14.]
M.A. Brown, L.G. Kennedy, A.J. MacGregor, C. Darke, E. Duncan, J.L. Shatford, et al.
Susceptibility to ankylosing spondylitis in twins: the role of genes, HLA, and environment.
[15.]
M.A. Brown, S.H. Laval, S. Brophy, A. Calin.
Recurrence risk modelling of the genetic susceptibility to ankylosing spondylitis.
Ann Rheum Dis, 59 (2000), pp. 883-886
[16.]
R.E. Hammer, S.D. Maika, J.A. Richardson, J.P. Tang, J.D. Taurog.
Spontaneous inflammatory disease in transgenic rats expressing HLA-B27 and human beta 2m: an animal model of HLA-B27-associated human disorders.
Cell, 63 (1990), pp. 1099-1112
[17.]
S. Weinreich, F. Eulderink, J. Capkova, M. Pla, K. Gaede, J. Heesemann, et al.
HLA B27 as a relative risk factor in ankylosing enthesopathy in transgenic mice.
Hum Immunol, 42 (1995), pp. 103-115
[18.]
J.D. Taurog, J.A. Richardson, J.T. Croft, W.A. Simmons, M. Zhou, J.L. Fernández-Sueiro, et al.
The germfree state prevents development of gut and joint inflammatory disease in HLA-B27 transgenic rats.
J Exp Med, 180 (1994), pp. 2359-2364
[19.]
S.D. Khare, J. Hansen, H.S. Luthra, C.S. David.
HLA-B27 heavy chains contribute to inflammatory disease in B27/human beta-2-microglobulin (beta2m) double transgenic mice with disrupted mouse beta2m.
J Clin Invest, 98 (1996), pp. 2746-2755
[20.]
T.M. Tran, M.L. Dorris, N. Satumtira, J.A. Richardson, R.E. Hammer, J. Shang, et al.
Additional human beta 2m curbs HLAB27 misfolding and promotes arthritis and spondylitis without colitis in male HLA-B27 transgenic rats.
Arthritis Rheum, 54 (2006), pp. 1317-1327
[21.]
M. Dougados, S. van der Linden, R. Juhlin, B. Huitfelt, B. Amor, A. Calin, et al.
The European Spondyloarthropathy Study Group preliminary criteria for the classification of spondyloarthropathy.
Arthritis Rheum, 34 (1991), pp. 1218-1227
[22.]
M.A. Khan.
Ankylosing spondylitis: introductory comments in its diagnosis and treatment.
Ann Rheum Dis, 61 (2002), pp. iii3-iii7
[23.]
W. Mau, H. Zeidler, R. Mau, A. Majewski, J. Freyschmidt, W. Stangel, et al.
Clinical features and prognosis of patients with possible ankylosing spondylitis. Results of a 10-year followup.
J Rheumatol, 15 (1988), pp. 1109-1114
[24.]
E. Feldtkeller, M.A. Khan, D. van der Heijde, S. van der Linden, J. Braun.
Age at disease onset and diagnosis delay in HLAB27 negative vs positive patients with ankylosing spondylitis.
Rheumatol Int, 23 (2003), pp. 61-66
[25.]
S.M. Van der Linden, H.A. Valkenburg, A. Cats.
Evaluation of the diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria.
Arthritis Rheum, 27 (1984), pp. 361-368
[26.]
A. Calin, B. Kaye, M. Sternberg, B. Antell, M. Chan.
The prevalence and nature of back pain in an industrial complex. A questionnaire and radiographic and HLA analysis.
Spine, 5 (1980), pp. 201-205
[27.]
M.R. Underwood, P. Dawes.
Inflammatory back pain in primary care.
Br J Rheumatol, 34 (1995), pp. 1074-1077
[28.]
M.A. Khan.
Clinical application of HLA-B27 test in rheumatic diseases: a current perspective.
Arch Intern Med, 140 (1980), pp. 177-180
[29.]
B.R. Hawkins, R.I. Dawkins, F.T. Christiansen, P.J. Zilko.
Use of the B27 test in the diagnosis of ankylosing spondylitis: a statistical evaluation.
Arthritis Rheum, 24 (1981), pp. 743-746
[30.]
M. Baron, I. Zendel.
HLA-B27 testing in ankylosing spondylitis: an analysis of the pretesting assumptions.
J Rheumatol, 16 (1989), pp. 631-634
Copyright © 2008. Sociedad Española de Reumatología
Opciones de artículo
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos